What is claimed is:

1. A compound of formula I as indicated below:



(I)

wherein

n is 0 or 1;

When X is nitrogen or oxygen, Y is nothing;

When Y is nitrogen or oxygen, X is nothing;

T is a sulfonyl group (SO2) or canbonyl group (CO) ;

When T=CO, X is oxygen or nitrogen;

Z^- is selected from the group consisting of halo, $CF3COO^-$, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

R1 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, C_3-C_8 alkenyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl.

R2 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl and C_3-C_8 cycloalkyl lower alkyl and heterocycle rings;

R3 is selected from the group consisting of an unsubstituted or substituted following group: phenyl, phenyl C1-C6 lower alkyl, thiophenyl, thiophenyl C1-C6 lower alkyl, furanyl, furanyl C1-C6 lower alkyl, pyridinyl, pyridinyl C1-C6 lower alkyl, imidazolyl, imidazolyl C1-C6 lower alkyl, naphthyl, naphthyl C1-C6 lower alkyl, quinolinyl, quinolinyl C1-C6 lower alkyl, indolyl, indolyl C1-C6 lower alkyl, benzothiophenyl, benzothiophenyl C1-C6 lower alkyl, benzofuranyl, benzofuranyl C1-C6 lower alkyl, benzoimidazolyl, benzoimidazolyl C1-C6 lower alkyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl C_1-C_6 lower alkyl, or C_3-C_8 alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, phenoxy, phenyl C_1-C_3 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, thiophenyl, thiophenyl C1-C3 lower alkyl, furanyl, furanyl C1-C3 lower alkyl, pyridinyl, pyridinyl C1-C3 lower alkyl, naphthyl, naphthyl C1-C3 lower alkyl, quinolinyl, quinolinyl C1-C3 lower alkyl, indolyl, indolyl C1-C3 lower alkyl, benzothiophenyl, benzothiophenyl C1-C3 lower alkyl, benzofuranyl, benzofuranyl C1-C3 lower alkyl, COOH, COR6, COOR6, CONHR6, CON(R6)2, COG, NHR6, N(R6)2, G, OCOR6, OCONHR6, NHCOR6, N(R6)COR6, NHCOOR6 and NHCONHR6;

R4 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl.

2. A. compound according to claim 1 selected from the group consisting of:

n is 0 or 1;

When X is nitrogen or oxygen, Y is nothing;

When Y is nitrogen or oxygen, X is nothing;

T is a sulfonyl group (SO2) or canbonyl group (CO) ;

When T=CO, X is oxygen or nitrogen;

Z^- is selected from the group consisting of halo, $CF3COO^-$, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

R1 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, C_3-C_8 alkenyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl.

R2 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl and C_3-C_8 cycloalkyl lower alkyl and heterocycle rings;

R3 is selected from the group consisting of an unsubstituted or substituted following group: phenyl, phenyl C1-C6 lower alkyl, thiophenyl, thiophenyl C1-C6 lower alkyl, furanyl, furanyl C1-C6 lower alkyl, pyridinyl, pyridinyl C1-C6 lower alkyl, imidazolyl, imidazolyl C1-C6 lower alkyl, naphthyl, naphthyl C1-C6 lower alkyl, quinolinyl, quinolinyl C1-C6 lower alkyl, indolyl, indolyl C1-C6 lower alkyl, benzothiophenyl, benzothiophenyl C1-C6 lower alkyl, benzofuranyl, benzofuranyl C1-C6 lower alkyl, benzoimidazolyl, benzoimidazolyl C1-C6 lower alkyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl C_1-C_6 lower alkyl, or C_3-C_8 alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, phenoxy, phenyl C_1-C_3 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy,

propylenedioxy, butylenedioxy, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, thiophenyl, thiophenyl C1-C3 lower alkyl, furanyl, furanyl C1-C3 lower alkyl, pyridinyl, pyridinyl C1-C3 lower alkyl, naphthyl, naphthyl C1-C3 lower alkyl, quinolinyl, quinolinyl C1-C3 lower alkyl, indolyl, indolyl C1-C3 lower alkyl, benzothiophenyl, benzothiophenyl C1-C3 lower alkyl, benzofuranyl, benzofuranyl C1-C3 lower alkyl, COOH, COR6, COOR6, CONHR6, CON(R6)2, COG, NHR6, N(R6)2, G, OCOR6, OCONHR6, NHCOR6, N(R6)COR6, NHCOOR6 and NHCONHR6;

R4 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl.

or a pharmaceutically acceptable salt thereof.

3. A. compound according to claim 1 selected from the group consisting of:

n is 0 or 1;

When X is nitrogen or oxygen, Y is nothing;

When Y is nitrogen or oxygen, X is nothing;

T is a sulfonyl group (SO2) or canbonyl group (CO) ;

When T=CO, X is oxygen or nitrogen;

Z^- is selected from the group consisting of halo, $CF3COO^-$, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

R1 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, C_3-C_8 alkenyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, phenyl and phenyl C1-C3 lower alkyl.

R2 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C1-C3 lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl and C_3-C_8 cycloalkyl lower alkyl and heterocycle rings;

R3 is selected from the group consisting of an unsubstituted or substituted following group: phenyl, phenyl C1-C6 lower alkyl, thiophenyl, thiophenyl C1-C6 lower alkyl, furanyl, furanyl C1-C6 lower alkyl, pyridinyl, pyridinyl C1-C6 lower alkyl, imidazolyl, imidazolyl C1-C6 lower alkyl, naphthyl, naphthyl C1-C6 lower alkyl, quinolinyl, quinolinyl C1-C6 lower alkyl, indolyl, indolyl C1-C6 lower alkyl, benzothiophenyl, benzothiophenyl C1-C6 lower alkyl, benzofuranyl, benzofuranyl C1-C6 lower alkyl, benzoimidazolyl, benzoimidazolyl C1-C6 lower alkyl, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl C_1-C_6 lower alkyl, or C_3-C_8 alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C_1-C_8 alkoxy, phenoxy, phenyl C_1-C_3 alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, thiophenyl, thiophenyl C1-C3 lower alkyl, furanyl, furanyl C1-C3 lower alkyl, pyridinyl, pyridinyl C1-C3 lower alkyl, naphthyl, naphthyl C1-C3 lower alkyl, quinolinyl, quinolinyl C1-C3 lower alkyl, indolyl, indolyl C1-C3 lower alkyl, benzothiophenyl, benzothiophenyl C1-C3 lower alkyl, benzofuranyl, benzofuranyl C1-C3 lower alkyl, COOH, COR6, COOR6, CONHR6, CON(R6)2, COG, NHR6, N(R6)2, G, OCOR6, OCONHR6, NHCOR6, N(R6)COR6, NHCOOR6 and NHCONHR6;

R4 is selected from the group consisting of C_1-C_8 branched or unbranched alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl lower alkyl.

4.

or a pharmaceutically acceptable salt thereof.

4. A. compound according to claim 1 selected from the group consisting of:
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(2,2,2-trifluoroethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(5-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(4-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-[({4-[(8-quinolinylsulfonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-({[4-({[3,4-bis(methyloxy)phenyl]sulfonyl}oxy)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(2-bromophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(4-fluorophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-[({4-[(phenylsulfonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(5-bromo-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-[({4-[(3-thienylsulfonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(2,2,2-trifluoroethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(5-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(4-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(5-chloro-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(methylsulfonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(propylsulfonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-({[4-({[2-(acetylamino)-4-methyl-1,3-thiazol-5-yl]sulfonyl}oxy)phenyl]amino}carbonyl)-*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-({[4-({[4-(phenylsulfonyl)-2-thienyl]sulfonyl}oxy)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(5-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(2-naphthalenylsulfonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(2,2,2-trifluoroethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(5-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(4-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-{[(4-{[(4-cyanophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-({[4-({[4-(trifluoromethyl)phenyl]sulfonyl}oxy)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-({[4-({[5-(3-isoxazolyl)-2-thienyl]sulfonyl}oxy)phenyl]amino}carbonyl)-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(3-fluorophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1,3,5-trimethyl-1*H*-pyrazol-4-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(5-methyl-4-isoxazolyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-{[(4-{[(3,5-dimethyl-4-isoxazolyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;

N-{[(4-{[(2,4-dichlorophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({4-[({4-[(trifluoromethyl)oxy]phenyl}sulfonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methyl-1*H*-imidazol-4-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-[({4-[(cyclohexylcarbonyl)oxy]phenyl}amino)carbonyl]-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-[({4-[(cyclohexylcarbonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({4-[(cyclohexylcarbonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({4-[(cyclohexylcarbonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-[({4-[(cyclohexylcarbonyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({4-[(2-methylpropanoyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({4-[(2-methylpropanoyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-[({4-[(2-methylpropanoyl)oxy]phenyl}amino)carbonyl]-L-tyrosinamide trifluoroacetate;

N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(1-methylethyl)amino]sulfonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

N-{(3*S*)-1-ethyl-1-[(3-hydroxyphenyl)methyl]-3-pyrrolidiniumyl}-*N*-{[(4-{[(1-methylethyl)amino]sulfonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

or any other pharmaceutically acceptable salt.

5. A compound according to claim 1 selected from the group consisting of:
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-((3*S*)-1-{[3,4-bis(methyloxy)phenyl]methyl}-1-methyl-3-piperidiniumyl)-*N*-{[(4-{[(1-methylethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(6-chloro-3-methyl-1-benzothien-2-yl) sulfonyl]oxy}phenyl)amino] carbonyl}-L-tyrosinamide trifluoroacetate;
N-{[(4-{[(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;
N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
N-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1-methylethyl) amino] sulfonyl}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate
or any other pharmaceutically acceptable salt, or non-salt form thereof.

6. A Pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.

7. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.

8. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.

9. A method according to claim 8 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.

10. A method according to claim 9 wherein administration is via inhalation via the mouth or nose.

11. A method according to claim 10 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.

12. A method according to claim 11 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.

13. A method according to claim 12 wherein the compound has a duration of action of 24 hours or more.

14. A method according to claim 13 wherein the compound has a duration of action of 36 hours or more.